There have been some exciting developments recently for Cancer Nanotechnology. In August, the journal joined the BMC family of journals, and in doing so, became a part of a brand that has been a true innovator in open access publishing since its founding in the late nineties.
Itself a pioneer as a research venue at the intersection of cancer research and nanotechnology, Cancer Nanotechnology is naturally at home with BMC, and those of us working the journal are delighted to be a member of this prestigious family. We look forward to this new chapter in the journal’s life, and we invite you to learn more about our new family by visiting the BMC homepage.
BMC is a part of Springer Nature, and thus we continue in our new brand to benefit from more than a century’s worth of experience from one of the world’s most renowned publishers.
There have also been big changes for our two Editors-in-Chief, both of whom have in the past few months moved to new institutions. Fred Currell is now Director of the University of Manchester’s Dalton Cumbrian Facility, a state-of-the-art research base for the UK and international radiation science community, where he leads a research program into nanoscale radiation processes related to cancer therapy and civil nuclear waste.
Steve Curley recently moved to CHRISTUS Mother Frances Hospital in Tyler, Texas, where he is the Director of the Oncology Institute. Steve also recently published a book about his experiences as surgical oncologist. Entitled In My Hands, it has been described as a “masterful presentation of how one of the leading cancer specialists world-wide approaches the patient burdened by malignancy”.
All of us at Springer Nature congratulate Fred and Steve on these achievements.
We are also delighted to welcome a new Editor-in-Chief to support Fred and Steve in the goal of making Cancer Nanotechnology a premiere venue for research in its field. Sunil Krishnan is the Director of the Center for Radiation Oncology Research at MD Anderson, Texas. We caught up with him to ask him a few questions about his research and his new role on the journal, and we’ll be featuring the interview with him on the blog in the coming days.
We welcome Sunil to his new role and wish him success as co-Editor-in-Chief.
If Cancer Nanotechnology is of interest to you and your research, please visit the website and sign up for article alerts to stay informed on the articles published in and news relating to the journal. We also welcome your next paper as a submission to the journal. Further, if you have an idea for a special article collection on a key topic that we are not yet covering, the journal editorial team would love to hear from you.
The mantra of BMC is “research in progress”. At Cancer Nanotechnology, our driving principle has always been “from basics to clinic”. Covering fundamental research all the way to clinical applications, Cancer Nanotechnology follows developments as they progress along the whole chain: research very much in progress. Our goal is to be one of the premiere research forums in this field, and as a part of BMC and with Sunil joining us, we are very much on the road towards achieving this. We invite you to join us on our journey.